
    
      A randomized, double-blind, placebo-controlled phase III study, to evaluate the efficacy,
      safety and tolerability of eltrombopag olamine (SB-497115-GR), a thrombopoietin receptor
      agonist, administered for 6 months as oral tablets once daily in adult subjects with
      previously treated chronic idiopathic thrombocytopenic purpura (ITP).
    
  